Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 02, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific executive share transaction.
Material Changes and Transaction Details
The filing details two related transactions involving Ms. C Thomas, Senior Vice President of Human Resources, occurring on April 28, 2017:
- Option Exercise: Exercise of a nil-cost option over 989 Ordinary Shares. The shares were granted on March 20, 2014, and vested on March 20, 2017, under the 2009 Deferred Annual Bonus Plan - Matching Award. The exercise price was £0.0000.
- Share Sale: Sale of 467 Ordinary Shares on the London Stock Exchange (XLON) at a price of £15.5450 per share. This sale was executed to meet tax liabilities arising from the option exercise.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a notification of a share transaction.
Investor Verification Points
- Verify the total number of shares held by Ms. C Thomas post-transaction (989 acquired, 467 sold).
- Confirm the tax implications and net share retention resulting from the Deferred Annual Bonus Plan.
- Check the prevailing market price of GSK shares on April 28, 2017, to contextualize the sale price of £15.5450.